Madhu Kumar
Stock Analyst at Goldman Sachs
(2.90)
# 1,582
Out of 4,786 analysts
153
Total ratings
55.45%
Success rate
19.02%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | $169 | $124.15 | +36.13% | 7 | Jun 5, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $2.88 | +108.33% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $17.45 | +49.00% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $14.08 | +20.74% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.23 | +225.20% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $180.30 | -14.03% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $40.19 | +31.87% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $3.86 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $12.74 | +473.00% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $21.87 | +544.72% | 9 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $34 | $12.29 | +176.76% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $3.33 | +80.18% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $10.59 | +32.20% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $12.97 | +61.91% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $22.00 | -77.27% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $1.16 | +589.66% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $7.02 | +1,167.81% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $6 | $0.35 | +1,599.24% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.49 | +1,945.41% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $7.11 | +1,095.50% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $1.24 | +3,045.16% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $10.60 | +437.74% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.49 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $2.04 | +44,017.65% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $6.48 | +208.64% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $1.24 | +7,964.52% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $32.15 | +8.86% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $0.31 | +19,565.68% | 1 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $5.42 | +638.01% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $9.56 | +5,171.97% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $270.02 | -14.82% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $60 | $1.75 | +3,328.57% | 5 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.02 | +3,821.57% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $39.43 | -45.47% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $34.03 | -30.94% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Jun 5, 2024
Initiates: Buy
Price Target: $169
Current: $124.15
Upside: +36.13%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $2.88
Upside: +108.33%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $17.45
Upside: +49.00%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $14.08
Upside: +20.74%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.23
Upside: +225.20%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $180.30
Upside: -14.03%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $40.19
Upside: +31.87%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.86
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $12.74
Upside: +473.00%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $21.87
Upside: +544.72%
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $12.29
Upside: +176.76%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $3.33
Upside: +80.18%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $10.59
Upside: +32.20%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $12.97
Upside: +61.91%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $22.00
Upside: -77.27%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $1.16
Upside: +589.66%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $7.02
Upside: +1,167.81%
Jan 19, 2022
Downgrades: Neutral
Price Target: $29 → $6
Current: $0.35
Upside: +1,599.24%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.49
Upside: +1,945.41%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $7.11
Upside: +1,095.50%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $1.24
Upside: +3,045.16%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $10.60
Upside: +437.74%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.49
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $2.04
Upside: +44,017.65%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $6.48
Upside: +208.64%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $1.24
Upside: +7,964.52%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $32.15
Upside: +8.86%
Feb 11, 2020
Initiates: Outperform
Price Target: $60
Current: $0.31
Upside: +19,565.68%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $5.42
Upside: +638.01%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $9.56
Upside: +5,171.97%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $270.02
Upside: -14.82%
Jul 6, 2018
Maintains: Neutral
Price Target: $120 → $60
Current: $1.75
Upside: +3,328.57%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $1.02
Upside: +3,821.57%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $39.43
Upside: -45.47%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $34.03
Upside: -30.94%